Hiroomi Nakatsu

Asahi General Hospital

Papers

1

Total Citations

4

H-Index

1

About

Hiroomi Nakatsu is a leading figure in urologic oncology, with a focused expertise in prostate cancer surgical management and risk stratification. His most impactful work centers on refining the selection criteria for extended pelvic lymph node dissection (ePLND) in the robotic surgery era. Recognizing the overtreatment risks of ePLND, Nakatsu developed and validated a novel nomogram specifically for Japanese patients undergoing robot-assisted radical prostatectomy. This tool, detailed in his 2023 study of 538 patients, provides a more precise, ethnicity-specific assessment of lymph node invasion risk, directly improving surgical decision-making and reducing unnecessary morbidity. With his work accumulating citations and shaping clinical guidelines, Nakatsu’s contributions represent a critical step toward personalized, data-driven urologic surgery. His research not only enhances oncologic outcomes but also underscores the importance of adapting global surgical protocols to regional patient populations, marking him as a key innovator in the field.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era
4 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Asahi General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago